TIL infusion

BIOLOGICAL6 trials

Sponsors

Inge Marie Svane, H. Lee Moffitt Cancer Center and Research Institute

Conditions

Melanoma (Skin)Metastatic MelanomaMetastatic Ovarian CancerMetastatic Renal Cell CarcinomaSkin Cancer

Early Phase 1

Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma

CompletedNCT02652455

H. Lee Moffitt Cancer Center and Research InstituteMelanoma (Skin), Skin Cancer

Start: 2016-03-08End: 2020-08-30Updated: 2025-08-19

Phase 1

Vemurafenib and TIL Therapy for Metastatic Melanoma

CompletedNCT02354690

Inge Marie SvaneMetastatic Melanoma

Start: 2014-11-30End: 2018-12-31Updated: 2020-03-23

Peginterferon and TIL Therapy for Metastatic Melanoma

CompletedNCT02379195

Inge Marie SvaneMetastatic Melanoma

Start: 2014-11-30End: 2018-10-31Updated: 2020-01-22

TIL Therapy for Metastatic Ovarian Cancer

CompletedNCT02482090

Inge Marie SvaneMetastatic Ovarian Cancer

Start: 2015-07-31End: 2017-04-30Updated: 2017-08-16

TIL Therapy for Metastatic Renal Cell Carcinoma

CompletedNCT02926053

Inge Marie SvaneMetastatic Renal Cell Carcinoma

Start: 2016-12-31End: 2021-10-31Updated: 2024-11-22

TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer

CompletedNCT03287674

Inge Marie SvaneMetastatic Ovarian Cancer

Start: 2017-10-09End: 2020-06-01Updated: 2023-03-01

Related Papers

CD40L stimulates tumor-infiltrating B-cells and improves ex vivo TIL expansion

Journal for ImmunoTherapy of Cancer2025-04-016 citations

612 Peripheral immune signature of responsiveness to adoptive cell therapy with ex vivo expanded TILs using high dimensional single cell analysis

Regular and Young Investigator Award Abstracts2022-11-01

Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma

Journal for ImmunoTherapy of Cancer2020-07-0153 citations

Treatment with tumor-infiltrating lymphocytes in the changing treatment landscape of metastatic melanoma.

Journal of Clinical Oncology2019-05-201 citations

Tumour-reactive T cell subsets in the microenvironment of ovarian cancer.

2019-02-0549 citations

Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor induction in checkpoint inhibitor resistant metastatic melanoma patients

Annals of Oncology2018-10-012 citations